Advertisement
Advertisement
PTCT
PTC Therapeutics, Inc.
71.02
USDSponsored
+0.71
+1.01%
May 20, 16:00 UTC -4
Closed
Pre-Market
71.52
+0.50
+0.70%
PTCT Earnings Reports
Positive Surprise Ratio
PTCT beat 15 of 42 last estimates.
36%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$295.43M
/$0.20
Implied change from Q1 26 (Revenue/ EPS)
+8.40%
/-766.67%
Implied change from Q2 25 (Revenue/ EPS)
+65.16%
/-124.10%
PTC Therapeutics, Inc. earnings per share and revenue
On May 07, 2026, PTCT reported earnings of -0.03 USD per share (EPS) for Q1 26, beating the estimate of -0.47 USD, resulting in a 93.75% surprise. Revenue reached 272.55 million, compared to an expected 223.18 million, with a 22.12% difference. The market reacted with a +14.27% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of 0.20 USD, with revenue projected to reach 295.43 million USD, implying an decrease of -766.67% EPS, and increase of 8.40% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Immuneering Corporation Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.29%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.04
Surprise
+12.85%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
Citius Oncology, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.01
Actual
-$1.43
Surprise
-13919.61%
Rein Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.19
Surprise
+61.98%
CervoMed Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.79
Actual
-$0.86
Surprise
-8.09%
Neuphoria Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.09
Surprise
+90.90%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were PTC Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, PTC Therapeutics, Inc. reported EPS of -$0.03, beating estimates by 93.75%, and revenue of $272.55M, 22.12% above expectations.
How did the market react to PTC Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved up 14.27%, changed from $64.49 before the earnings release to $73.69 the day after.
When is PTC Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for PTC Therapeutics, Inc.'s next earnings report?
Based on 10
analysts, PTC Therapeutics, Inc. is expected to report EPS of $0.20 and revenue of $295.43M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement